Earnings Call · Q2 FY2023·2023-08-08

Q2 23EPS +40.51%·Rev n/aQ1 23EPS +31.51%·Rev n/aQ4 22EPS 0.00%·Rev n/aQ3 22EPS +1.56%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Investor Relations or Corporate Communications (likely) - Call Moderator

Fred Vogt — Interim President and Chief Executive Officer

Igor Bilinsky — Chief Operating Officer

Jim Ziegler — Executive Vice President, Commercial

Friedrich Finckenstein — Senior Executive (likely Chief Medical Officer or similar)

Jean-Marc Bellemin — Chief Financial Officer or Senior Finance Executive

+6.4%1d on move date+7.1% vs SPY3d−1.1%5d+5.2%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access